An overview of Valirx plc

An Overview Of Valirx Plc

ValiRx Plc is a biopharmaceutical development company developing cancer-related therapeutic and diagnostic technologies. We want to make a significant contribution to technological breakthroughs for human health and well-being by developing and marketing novel, cost-effective, high-quality, safe and effective therapeutics. [Sources: 2, 3]

ViRx’s GeneICE ™ technology platform uses the ability to silence genes specifically involved in cancer by targeting anti-apoptotic genes. Geneice ™ works by silencing complexes known as histone deacetylase complexes (HDACs) in the presence of a targeted gene involved in the progression of cancer cells. Black Cat Bio is the developer of VAL401, which is entering the next phase of clinical trials independently of Vali Rx. Currently, Vali rx uses the gene ICE (m) platform to target other genes involved in diseases, including those targeting neurological diseases, and is currently using it to target genes that cause cancer. [Sources: 4, 5]

Data processing and statistical analysis will then lead to overall results, including safety, tolerability, indication and effects on diseases that will be communicated to the market in due course. These results will then feed into a clinical trial report and submission of the regulatory documents expected in the fourth quarter of 2020. [Sources: 5]

A copy of the Circular is available for download from the Company’s ValiRx Plc website at You can view the full document below and find at the end of this document a notice to convene a general meeting to be held on Tuesday, 30 October 2018 at 10: 00 (CET) in the ValirX boardroom, Cross Street, London, England. [Sources: 0]

The purpose of this document is to provide shareholders with details of the capital reorganisation and to explain why the Board of Directors recommended that shareholders vote in favour of Resolution 1 at the Annual General Meeting. As the notice is at the end of this document, the capital reorganization requires the approval of shareholders at this Annual General Meeting. [Sources: 0]

The application will be filed with the London Stock Exchange to allow the New Common Shares to be traded on AIM in place of the existing Common Shares. Subject to shareholder approval of this resolution, the admission is expected to take effect and transactions in new common shares are expected to commence on or around February 18, 2020, subject to approval by the Board of Directors at this Annual General Meeting. The application for admission to trading on AIPA (“AIM”) has been filed, as has the admission of all new common shareholders to the Company’s common shares, which is expected to take place on February 18, 2020. The applications will decide whether or not to admit the new Ordine shares so that they can be traded at aIM and, if so, on what terms and at what price. Reception: An application for admission to new Ordination units has been made or will be made, in which case treatment with them will only begin on the day of admission. Admissions: Decisions to admit new shares in the event of a change of control, issue shares and / or accept a bid. Trading in these new Ordinary Shares is expected to commence around 16 February 2019, with trading in these Shares expected to commence on / on 18 January 2020 and will have a price of $1.00 per share. [Sources: 0]

The Annual General Meeting is held and convened at the Company’s headquarters in London, England, by the Board of Directors of Valirx PLC, the “Board” of Directors. [Sources: 0]

RNS has been approved by the Financial Conduct Authority as the primary information provider in the UK. The company operates Morphogenesis, Inc., a UK-based company developing and researching epigenetic drugs that is developing the world’s first oncology diagnostic for the treatment of multiple sclerosis (“morphogenesis”). The company is bringing its emerging drug diagnostics business to Greater China, with an initial focus on oncolysis, and its Belgium-based onocephaly diagnostic operations. CRONOS has a global portfolio of potentially marketable technologies – changing technologies in biotechnology, biopharmaceuticals, pharmaceuticals and biomedicine. [Sources: 1, 2, 4]

The Experimental Science Programme builds on CRONOS “extensive experience in demonstrating evidence-based concepts and supporting discussions on commercial development. [Sources: 5]

Michael Chermak, Chairman and CEO of Bridgetech, said, “We are very excited about the potential of ValiRx for the development and commercialization of CRONOS. Commenting on the results, Dr. Satu Vainikka, CEO of ValoRX, said: “These first in vivo data are an important step in the clinical development of the first ever in vivo trial of a new drug candidate for cancer treatment in human patients with a severe and potentially life-threatening form of cancer.” said Dr. Satu Vainsikkas, CEO of vali Rx: “Valirx is pleased to have successfully completed our first clinical trial on an animal model of an in vitro medicine. [Sources: 2, 4]

Based on these results, the company has initiated further preclinical studies to enter the VAL phase. I have applied for authorisation for toxicological studies. The most advanced product is ImmuneFx ™, for which we recently received a patent from the US Patent Office. VAL301 will continue to be evaluated for the treatment of endometriosis and, as announced on 1 May 2020, for the treatment of multiple sclerosis (MS). [Sources: 2, 4, 5]